Hematology/Oncology Department
Research Studies Open for Enrollment
|
UCSF Benioff Children's Hospital Oakland Hematology/Oncology Department Research Studies Open for Enrollment |
Date: 07/13/2020 |
|---|
| Title | ID/Protocol | NCT/Phase | Sponsor | P.I. | Contact |
| Multi-center, randomized, open-label, parallel-group study with LPC-401 for the treatment of myocardial iron overload in adult patients with transfusion-dependent beta-thalassemia | HEPCIDIN | NCT03381833 Phase 2 | La Jolla Pharmaceutical Company | Ashutosh Lal, MD | Ricarda Sawatzki (510-428-3885 x5361) |
| Single-Center, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses with Alpha Thalassemia Major | IUHCT | NCT02986698 Phase 1 | UC San Francisco | Elliott Vichinsky, MD | Elliott Vichinsky, MD (510-428-3885 x3651) |
| Allogeneic Stem Cell Transplantation of CordIn (Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells) in Patients with Hemoglobinopathies | CordIn | NCT02504619 Phase 1/2 | Gamida Cell Ltd | Mark Walters, MD | Marci Moriarty, RN (510-428-3385 x5396) |
| Long Term Follow Up for Patients who have received Allogeneic Stem Cell Transplantation of NiCord/CordIn, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells | NiCord | N/A | Gamida Cell Ltd | Mark Walters, MD | Julie Decaris (510-428-3385 x2739) |
| Sample Collection of Bone Marrow, Blood, Peripheral Blood Stem Cells or Umbilical Cord Blood from Patients with Genetic Diseases Affecting the Blood Cells | BMT-repository | N/A | California Institute for Regenerative Medicine | Mark Walters, MD | Marci Moriarty, RN (510-428-3385 x5396) |
| Evaluating Efficacy and Safety of Gene Therapy in Transfusion-dependent Beta-Thalassemia Beta0/Beta0 Genotype by Autologous Transplantation of CD34+ Stem Cells Transduced Ex Vivo with Lentiviral BA-T87Q Globin Vector in Subjects < 50 Years | Hgb-212 | NCT02906202 Phase 3 | Bluebird Bio | Ashutosh Lal, MD | Marci Moriarty, RN (510-428-3885 x5396) |
| Open-label, Single-arm Study to Assess Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-dependent Beta thalassemia (TDT) | ST-400-01 | NCT03432364 Phase 1/2 | Sangamo Therapeutics, Inc. | Mark Walters, MD | Marci Moriarty, RN (510-428-3885 x5396) |